Literature DB >> 10724506

Secondary heterotypic versus homotypic infection by Coxsackie B group viruses: impact on early and late histopathological lesions and virus genome prominence.

J Z Yu1, J E Wilson, S M Wood, R Kandolf, K Klingel, D Yang, B M McManus.   

Abstract

The impact of prior exposure to a different or identical strain of Coxsackievirus B (CVB) on murine CVB myocarditis was studied using a susceptible murine host (A/J[H-2a]) and myocarditic CVB3 or avirulent CVB2 as primary or secondary infectants. The effects of secondary heterotypic infection (CVB2 followed by CVB3) and homotypic infection (CVB3 followed by CVB3) 28 days after primary inoculation, versus CVB2 or CVB3 alone, on injury and viral genomic replication, both early (day 7) and late (days 28 and 56), were evaluated. After the primary infection by CVB2, trivial viral RNA was present in the heart and other organs, and a substantial positivity was observed with CVB3 infection. Seven days after secondary heterotypic (CVB2-CVB3) infection, the quantity of CVB genome in heart, pancreas, liver, and spleen was increased compared with the virus genome in the CVB3-CVB3 group and in the group with primary CVB3 infection alone. This phenomenon was seen in the heart and spleen up to day 28 postsecondary infection. Tissue inflammation and necrosis in heart and pancreas were prominent 7 days postsecondary infection with CVB2-CVB3 and correlated well with an increased quantity of CVB genome. Virus genome was present in heart and spleen 28 days after CVB3 infection alone. Serum CVB3 neutralization titer was increased to 1:128 in CVB2-CVB3 group at days 7 and 28 postsecondary infection, and serum completely neutralized cytopathological effects of CVB3 in the CVB3-CVB3 group at day 7 and 28 postsecondary infection. Our results indicate that secondary heterotypic infection by CVB causes increased injury, inflammation, and CVB replication in target organs such as the heart and pancreas, as well as in immune compartments like the spleen. Compared with CVB3 alone, the intense inflammatory infiltriate in the CVB2-CVB3 group is as not due solely to postviral sensitization of the immune system, but rather to the inability of the host to eradicate the virus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10724506     DOI: 10.1016/s1054-8807(98)00025-8

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  6 in total

1.  Anti-coxsackievirus B4 (CV-B4) enhancing activity of serum associated with increased viral load and pathology in mice reinfected with CV-B4.

Authors:  Firas Elmastour; Hela Jaïdane; Mehdi Benkahla; Leila Aguech-Oueslati; Famara Sane; Aymen Halouani; Ilka Engelmann; Antoine Bertin; Moncef Mokni; Jawhar Gharbi; Mahjoub Aouni; Enagnon K Alidjinou; Didier Hober
Journal:  Virulence       Date:  2016-10-28       Impact factor: 5.882

2.  A single coxsackievirus B2 capsid residue controls cytolysis and apoptosis in rhabdomyosarcoma cells.

Authors:  Maria Gullberg; Conny Tolf; Nina Jonsson; Charlotta Polacek; Jana Precechtelova; Miriam Badurova; Martin Sojka; Camilla Mohlin; Stina Israelsson; Kjell Johansson; Shubhada Bopegamage; Susan Hafenstein; A Michael Lindberg
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

3.  Immunoglobulin G-dependent enhancement of the infection with Coxsackievirus B4 in a murine system.

Authors:  Firas Elmastour; Hela Jaidane; Leila Aguech-Oueslati; Mehdi Ayech Benkahla; Mahjoub Aouni; Jawhar Gharbi; Famara Sane; Didier Hober
Journal:  Virulence       Date:  2016-03-30       Impact factor: 5.882

4.  Enterovirus infections: Pivoting role of the adaptive immune response.

Authors:  Shubhada Bopegamage
Journal:  Virulence       Date:  2016-04-08       Impact factor: 5.882

5.  Mesenchymal Stromal Cells Modulate Monocytes Trafficking in Coxsackievirus B3-Induced Myocarditis.

Authors:  Kapka Miteva; Kathleen Pappritz; Muhammad El-Shafeey; Fengquan Dong; Jochen Ringe; Carsten Tschöpe; Sophie Van Linthout
Journal:  Stem Cells Transl Med       Date:  2017-01-03       Impact factor: 6.940

6.  Prior immune exposure can protect or can enhance pathology in the enteroviruses: what predicts the outcome?

Authors:  Nora M Chapman
Journal:  Virulence       Date:  2016-12-09       Impact factor: 5.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.